New drug combo tested for Tough-to-Treat cancers

NCT ID NCT06271837

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study is testing an experimental drug called trastuzumab deruxtecan (T-DXd), either alone or combined with other cancer drugs, for people with advanced solid tumors that have a specific marker called HER2. The goal is to see if the treatment can shrink tumors and control the cancer in patients who are not eligible for treatments aimed at a cure. Researchers will measure how well the tumors respond and monitor side effects in about 175 participants.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS (EXCLUDING GASTRIC CANCER AND BREAST CANCER) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
RECRUITING

Beijing, 100142, China
Research Site
RECRUITING

Beijing, 100191, China
Research Site
RECRUITING

Changchun, 130021, China
Research Site
RECRUITING

Changsha, 410013, China
Research Site
WITHDRAWN

Changzhou, 213004, China
Research Site
RECRUITING

Chengdu, 610041, China
Research Site
RECRUITING

Chongqing, 400030, China
Research Site
RECRUITING

Dongyang, 322100, China
Research Site
RECRUITING

Guangzhou, 510145, China
Research Site
RECRUITING

Guangzhou, 510630, China
Research Site
WITHDRAWN

Haikou, 570311, China
Research Site
RECRUITING

Hangzhou, 310003, China
Research Site
RECRUITING

Hangzhou, 310016, China
Research Site
RECRUITING

Hangzhou, 310022, China
Research Site
RECRUITING

Harbin, 150081, China
Research Site
RECRUITING

Hefei, 230031, China
Research Site
RECRUITING

Kunming, 650118, China
Research Site
RECRUITING

Lishui, 323000, China
Research Site
RECRUITING

Nanchang, 330029, China
Research Site
RECRUITING

Shandong, China
Research Site
RECRUITING

Shanghai, 200001, China
Research Site
RECRUITING

Shanghai, 200011, China
Research Site
RECRUITING

Shanghai, 200032, China
Research Site
RECRUITING

Shenyang, 110016, China
Research Site
RECRUITING

Taiyuan, 030001, China
Research Site
RECRUITING

Wuhan, 430022, China
Research Site
RECRUITING

Xi'an, 710061, China
Research Site
RECRUITING

Xuzhou, 221009, China
Research Site
RECRUITING

Yinchuan, 750004, China
Research Site
RECRUITING

Zhengzhou, 450002, China
Research Site
RECRUITING

Zhengzhou, 450008, China

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMORS (EXCLUDING GASTRIC CANCER AND BREAST CANCER)